IN8bio is a biotechnology business based in the US. IN8bio shares (INAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.32 – a decrease of 4.32% over the previous week. IN8bio employs 39 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.32 |
|---|---|
| 52-week range | $0.22 - $2.48 |
| 50-day moving average | $0.30 |
| 200-day moving average | $0.82 |
| Wall St. target price | $6.25 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.74 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.317 from 2024-11-19
| 1 week (2024-11-15) | -5.46% |
|---|---|
| 1 month (2024-10-22) | -3.35% |
| 3 months (2024-08-22) | -39.05% |
| 6 months (2024-05-22) | -69.81% |
| 1 year (2023-11-22) | -56.58% |
|---|---|
| 2 years (2022-11-22) | -77.36% |
| 3 years (2021-11-22) | 6.44 |
| 5 years (2019-11-18) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -77.64% |
| Return on equity TTM | -180.45% |
| Profit margin | 0% |
| Book value | $0.58 |
| Market Capitalization | $24.4 million |
TTM: trailing 12 months
We're not expecting IN8bio to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, IN8bio's shares have ranged in value from as little as $0.217 up to $2.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IN8bio's is -0.069. This would suggest that IN8bio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, IN8bio has bucked the trend.
To put IN8bio's beta into context you can compare it against those of similar companies.
IN8bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.